Drug Research

Thermo Fisher Scientific Inc., the world leader in serving science, and SRI International, a research center that creates world-changing solutions, today announced the results of a collaboration agreement to enable researchers to combine the results of high-resolution Orbitrap LC/MS...

eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence...

Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. No...

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the EC  has approved Rixathon® (biosimilar rituximab*) for use in Europe**. Rixathon is approved for use in all indications of the reference medicine, MabThera®...

Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a multi-year agreement with Takeda Pharmaceutical Company Limited under which Numerate will identify and deliver...

Eisai Co Ltd announced that it has entered into a new joint research agreement with the Broad Institute , a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new...

OBI Pharma, Inc., a Taiwan biopharma company announced an agreement with Threshold Pharmaceuticals, Inc. to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).  The product will...